Experimental Therapeutics

项目概要/摘要 实验治疗学（ET）计划的研究重点是识别，开发和测试 新的癌症疗法这是通过三个重叠的具体目标实现的，这些目标集中在1） 确定潜在的目标和发现治疗线索，2）进行临床前评价， 有前途的新治疗方法，和3）评估创新和有前途的药物，组合， 在临床试验中监测反应的方法。研究人员高度合作。关键科学 ET研究人员在前一个资助期内的成就包括确定新的治疗方法， 子宫内膜癌和骨髓瘤的靶点，基于纳米颗粒的药物开发，癌症免疫治疗 基于Toll样受体（TLR 9）激动剂，使用药理学抗坏血酸盐来增强功效， 减少化疗和放疗的毒性（与FRMI计划合作），以及 扩大促发剂启动和I期能力，包括病灶内治疗试验。有28 ET的正式成员和16名准成员，包括实验室、翻译和临床研究者 横跨五所学院的十三个系年度同行评审癌症直接费用总额 最近一个预算年度为270万美元（190万美元来自NCI）。额外资金包括380万美元， 非同行评审的研究项目。ET成员高度协作， 过去5年中有291篇癌症相关同行评审出版物，其中24%（n= 69）为项目内出版物，43%为 （n= 124）方案间出版物，42%（n= 123）机构间出版物。二十九篇手稿 发表在高影响力期刊上（影响因子≥10）。

PROJECT SUMMARY/ABSTRACT Research in the Experimental Therapeutics (ET) program focuses on identification, development and testing of new cancer therapeutics. This is accomplished through three overlapping specific aims centered on 1) identifying potential targets and discovering therapeutics leads, 2) conducting preclinical evaluation of promising new therapeutic approaches, and 3) evaluating innovative and promising agents, combinations, and approaches to monitoring response in clinical trials. ET investigators are highly collaborative. Key scientific achievements of ET investigators over the prior funding period include identification of novel therapeutic targets in endometrial cancer and myeloma, nanoparticle based drug development, cancer immunotherapy based on toll-like receptor (TLR9) agonists, use of pharmacologic ascorbate to enhance the efficacy and reduce the toxicity of both chemotherapy and radiation therapy (in collaboration with the FRMI Program), and expansion of investigator-initiated and Phase I capabilities including trials of intralesional therapy. There are 28 full and 16 associate members of ET including laboratory-based, translational and clinical investigators spanning 13 departments across five colleges. Annual total peer-reviewed cancer direct costs in the most recent budget year was $2.7 million ($1.9 million from the NCI). Additional funding included $3.8 million for non-peer-reviewed research projects. ET members are highly collaborative having authored or co-authored 291 cancer-related peer-reviewed publications in the past five years, with 24% (n= 69) intraprogrammatic, 43% (n= 124) interprogrammatic, and 42% (n= 123) interinstitutional publications. Twenty-nine manuscripts appeared in high impact journals (Impact Factor ≥10).